logo

For the Inventor, By the Inventor

Mystic, CT, United States of America

Eric R Larson

This inventor holds 17 USPTO granted patents. Top assignees: Pfizer Corporation, Osi Pharmaceuticals, Inc., Scios Inc.. Active years: 1987-2010.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Eric R Larson. Retrieved from https://idiyas.com/inventor/eric-r-larson

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 17

% Patents Active = 88.2

Average Co-Inventor Count = 2.5

ph-index = 7

Forward Citations = 211(Granted Patents)


Location History:

  • Guilford, CT (US) (1990)
  • Groton, CT (US) (1991 - 1992)
  • Stonington, CT (US) (1996 - 1998)
  • Mystic, CT (US) (1987 - 2010)

Company Filing History:

goldMedal17 out of 4,488 
 
Pfizer Corporation
 patents
silverMedal2 out of 118 
 
Osi Pharmaceuticals, Inc.
 patents
bronzeMedal2 out of 82 
 
Scios Inc.
 patents
4. 1 out of 40 
 
Scios Nova, Inc.
 patents
where one patent can have more than one assignee

Years Active: 1987-2010

Loading Chart...
17 patents (USPTO):Explore Patents
1. 7790902 - Isothiazole derivatives useful as anticancer agents (2010-09-07),
2. 7405218 - Isothiazole derivatives useful as anticancer agents (2008-07-29),
3. 6756388 - Benzothiophenes and related compounds as estrogen agonists (2004-06-29),
4. 6548526 - Isothiazole derivatives useful as anticancer agents (2003-04-15),
5. 6235764 - Isothiazole derivatives useful as anticancer agents (2001-05-22),
6. 5789415 - Azacyclic-heterocyclic compounds as angiotension II receptor antagonists (1998-08-04),
7. 5583137 - Heterocyclic compounds for enhancing antitumor activity (1996-12-10),
8. 5536722 - Triazine derivatives for enhancing antitumor activity (1996-07-16),
9. 5491234 - Pyrimidine derivatives for enhancing antitumor activity (1996-02-13),
10. 5446020 - Method of treating diabetes with tissue-selective insulin analogs (1995-08-29),
11. 5444062 - Quinazolines derivatives for enhancing antitumor activity (1995-08-22),
12. 5294635 - Heterocyclic compounds as aldose reductase inhibitors (1994-03-15),
13. 5268453 - Tissue-selective insulin analogs (1993-12-07),
14. 5175179 - Method for treating hypertension (1992-12-29),
15. 5039672 - Heterocyclic compounds as aldose reductase inhibitors (1991-08-13),

Title: Eric R. Larson: Pioneering Innovator Shaping the Future of Technology

Introduction:

Eric R. Larson, a distinguished inventor hailing from Mystic, CT (US), is celebrated for his unwavering commitment to innovation and his insatiable quest for excellence in the realm of technology. With an impressive portfolio of 17 patents to his name, Larson continues to leave an indelible mark on the world of inventiveness.

Latest Patents:

Among Larson's latest patents is his groundbreaking work on Isothiazole derivatives that exhibit promising potential as anticancer agents. The compounds he has developed hold significant implications for the treatment of hyperproliferative disorders in mammals. His inventive spirit and dedication to advancing healthcare solutions are vividly showcased through these latest patents.

Career Highlights:

Larson's illustrious career has seen him contribute significantly to renowned companies such as Pfizer Corporation and OSI Pharmaceuticals, Inc. His innovative prowess and visionary approach have been instrumental in driving forward groundbreaking research and development initiatives within these esteemed organizations. Larson's invaluable contributions have not only propelled advancements in pharmaceuticals but have also paved the way for transformative technological innovations.

Collaborations:

Throughout his career, Larson has collaborated closely with esteemed peers such as Mark Carl Noe and Thomas George Gant. Together, they have synergized their expertise and ingenuity to push the boundaries of invention and bring forth novel solutions to complex challenges. Larson's collaborative spirit and ability to inspire those around him have fostered a culture of innovation that continues to inspire the next generation of inventors.

Conclusion:

In conclusion, Eric R. Larson stands as a beacon of creativity and innovation, shaping the future of technology through his groundbreaking inventions and relentless pursuit of excellence. His passion for pushing the boundaries of possibility serves as a source of inspiration for aspiring inventors and underscores the transformative power of innovation in driving societal progress. Eric R. Larson's legacy as a pioneering innovator is destined to endure, influencing generations to come and leaving an indelible imprint on the landscape of technological advancement.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…